Compare Cassava Sciences Inc (FLNA) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs United Microelectronics Corp — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while United Microelectronics Corp trades at $23.07 (market cap $58.02B). The key difference: United Microelectronics Corp is far larger — about 1472.6× Cassava Sciences Inc's market cap, and United Microelectronics Corp pays a 1.76% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and United Microelectronics Corp for 42 Days on average.
| FLNA | UMC | |
|---|---|---|
Market Cap | $39.40M | $58.02B |
Volume | 759,018 | 11,897,809 |
Sector | Health | Technology |
52-Week High | $4.64 | $28.02 |
52-Week Low | $0.68 | $7.02 |
Typical Hold Time | 37 Days | 42 Days |
Enterprise Value | -$43.28M | $55.10B |
Dividend Yield | — | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
UMC trades at $23.31, up 0.52% with a bullish technical signal despite mixed moving averages. The company shows strong profitability with 32.75% net margin and 21.03% ROE, though revenue growth has moderated from 2022 peaks. Recent earnings beats and a Zacks Strong Buy upgrade (September 17, 2026) highlight positive momentum, while cash flow turned positive in 2025 after two years of outflows.
The stock presents growth potential with expanding AI opportunities and strong 22/28nm demand, but faces risks from semiconductor cycle volatility and competitive pressures. Analyst consensus is mixed with 27% buy ratings versus 20% sell, suggesting cautious optimism amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
